Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.
Australia’s inflation rate recently reached 4%, and the Reserve Bank lifted its cash rate target to 4.60%, partly linked to the artificial intelligence boom. Higher funding costs can pressure many sectors. Healthcare groups using AI to improve diagnoses, tailor treatments and run hospitals more efficiently could still attract attention. This article highlights three Australian AI healthcare stocks from our focused screener that investors may want on their watchlist. The three stocks below are...
The analyst fair value estimate for Amneal Pharmaceuticals has shifted from US$22.00 to about US$22.71 per share, reflecting updated price targets within the US$20 to US$27 range that are guiding much of the current discussion. Analysts are tying these targets to how effectively Amneal Pharmaceuticals turns its new products, biosimilars platform, and recent acquisitions into durable earnings power. As you read on, you will see how this evolving narrative may shape your own view of the stock’s...
Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end. PBH is a chroni
In September 2026, GRAIL announced that its Galleri multi-cancer early detection blood test showed strong performance in the PATHFINDER 2 study and received a favorable U.S. FDA advisory committee vote supporting its safety, benefit-risk profile and effectiveness for use alongside standard screening in adults aged 50 and older. The PATHFINDER 2 data indicated that adding Galleri increased cancers detected through screening more than six-fold with a very low false-positive rate, while the...
Bond yields have surged to levels not seen in decades, mortgage rates now sit above 7% and big institutional players are pulling back from Treasuries. That combination is reshaping how investors think about risk, cash flow and balance sheet strength. This piece walks through three large cap stocks exposed to these rate moves, all filtered for solid free cash flow, to help you judge which stories might deserve a closer look now. The three examples below are only a sample set, and the full...
Medtronic plc (NYSE:MDT) has been a bit of a slow burner. The company has a huge medical-device business and a dependable dividend, but growth has been difficult to find over the past few years. For investors, that has made Medtronic more of an income and stability play than a stock with much excitement around it. […]
BillionToOne’s updated analyst narrative now centers on a fresh Fair Value price target of US$128.57, compared with the prior US$122.14 level in this framework. Recent Street research links this adjustment to enthusiasm around the company’s technology and market reach, while also reflecting new questions on reimbursement risk and long term pricing power. As you read on, you will see how these moving pieces shape the evolving story around BillionToOne and what to watch as the narrative changes...
Greek inflation at 5.1% and energy prices jumping 25.4% year over year have turned the country’s power sector into a pressure cooker, with households squeezed and producers holding rare pricing power. That kind of stress can reset winners and laggards faster than many investors react. This article breaks down three Greek energy producers and utilities exposed to these shocks so you can judge where risk and potential opportunity might lie. The stocks covered below are only a sample, with the...
Edgewise Therapeutics (EWTX) drew fresh attention after scheduling a special call on September 22, 2026, to walk through the differentiated mechanism of action for its cardiac sarcomere modulator EDG-7500. The special EDG-7500 call lands after a powerful run for Edgewise Therapeutics, with a year to date share price return of 74.32% and a 1 year total shareholder return of 164.54%. However, the 30 day share price return declined 1.38%, suggesting that strong long term momentum may be pausing...
Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spend billions developing a drug only to see a competitor produce something better. That makes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]
Shares of healthcare services provider BrightSpring Health Services (NASDAQ:BTSG) jumped 4.8% in the afternoon session after BMO Capital analyst Sean Dodge reiterated an Outperform rating and a $70 price target on the company, StreetInsider reported.
Spiking Treasury yields have pushed many investors back toward safer assets, which has punished weaker balance sheets and rewarded stronger ones. That creates an opening for you. Solid, low priced companies that already showed gains over the past year and still look cheap on fundamental metrics suddenly look more interesting. This article examines three such penny stocks that combine financial resilience with positive analyst growth forecasts. The three elite penny stocks in this article are...
Celcuity (CELC) has moved into a new phase, with REVTORPYK now commercially available in the US for certain advanced breast cancer patients, paired with a support program that targets access, affordability, and treatment logistics. Despite REVTORPYK’s US launch and the recent appointment of seasoned finance leader David W. Gryska to Celcuity’s board, the share price has pulled back, with the 30 day share price return down 25.1% and the 1 year total shareholder return still up 42.7%. This...
Intuitive Surgical, Inc. (NASDAQ:ISRG) more or less invented modern robotic surgery with its da Vinci system, and for two decades it had the field to itself. The stock has now fallen about 35% from its high to roughly $395, yet it still trades near 46 times earnings and at $140 billion in value. So here […]
Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis. The company said that, among evaluable lupus nephritis patients, 50%
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternativesSAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that its Board of Directors has declared a special stock dividend (the "Special Stock Dividend") to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026. The Special Stock Dividend will consist of the Company's Se
Light AI Inc. ("Light AI" or the "Company") (Cboe CA: ALGO; (FSE: 0HC) (OTCQB: OHCFF) today announced that it will keep its QuickScan™ Strep A software-as-a-medical-device ("SaMD") in controlled product development and continue its hold on related clinical activities.
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that it will present the latest preclinical results of its novel costimulatory T cell engager (Cos-TCE) platform in a Rapid Oral Abstract Presentation at the 2026 Society for Immunotherapy
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.